Empaveli

Active Ingredient(s): Pegcetacoplan
FDA Approved: * May 14, 2021
Pharm Company: * APELLIS PHARMACEUTICALS INC
Category: Genetic Disorders

Pegcetacoplan, sold under the brand name Empaveli among others, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PNH).[2][3][4][5] The most common side effects include injection-site reactions, infections, diarrhea, abdominal pain, respiratory tract infection, viral infection, and fatigue.[2][4] Paroxysmal nocturnal hemoglobinuria is characterized by red blood cell destruction, a... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.